Every year, pharmaceutical companies abandon tens of thousands of patents and patent applications — quietly, deliberately, and in ways that […]
How Abandoned Drug Patents Become Your Competitive Weapon Read Post »
The pharmaceutical industry is entering a $400 billion revenue transfer. Between 2025 and 2030, nearly 200 blockbuster drugs will lose
When Blockbusters Fall, Business Development Rises: Win the Patent Cliff Read Post »
The Metamorphosis of the Global GLP-1 Market: A Strategic Overview The pharmaceutical landscape is currently undergoing a structural transformation of
The pharmaceutical industry has a new problem it didn’t anticipate when it started pouring billions into artificial intelligence: the machines
Algorithms Don’t Own Patents: How to Win the AI Drug Race Read Post »
The numbers are not abstract. Between 2025 and 2030, branded pharmaceutical products generating roughly $400 billion in annual global revenue
Build Your Drug Portfolio’s Moat Before the $400 Billion Patent Cliff Swallows It Read Post »
Full drug development — from first synthesis of a new chemical entity to FDA approval — costs, on average, $2.6
Cut Drug R&D Costs by 90%: The 505(b)(2) Playbook the Big Pharma Textbook Ignores Read Post »
The FDA Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, is the primary trade ledger
Profit from the Patent Cliff: ANDA Filing Trends Hidden Inside the FDA Orange Book Read Post »
The Food and Drug Administration (FDA) Orange Book is the primary financial barrier between a blockbuster drug and its generic
Own the Market: How Brand Companies Strategically List Patents in the FDA Orange Book Read Post »
The pharmaceutical market operates as a system of time-limited monopolies where the legal strength of a patent portfolio dictates the
Own the Generic Entry Timeline: From Orange Book Listing to At-Risk Launch Read Post »
Get fresh news and insights, drug patent expirations & more…
